JP2020055828A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020055828A5 JP2020055828A5 JP2019215918A JP2019215918A JP2020055828A5 JP 2020055828 A5 JP2020055828 A5 JP 2020055828A5 JP 2019215918 A JP2019215918 A JP 2019215918A JP 2019215918 A JP2019215918 A JP 2019215918A JP 2020055828 A5 JP2020055828 A5 JP 2020055828A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound according
- compound
- solution
- ligase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 34
- 239000000243 solution Substances 0.000 claims 15
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 12
- 102000003960 Ligases Human genes 0.000 claims 11
- 108090000364 Ligases Proteins 0.000 claims 11
- 239000004471 Glycine Substances 0.000 claims 6
- 239000003550 marker Substances 0.000 claims 6
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 5
- 235000004279 alanine Nutrition 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 235000001014 amino acid Nutrition 0.000 claims 4
- 229940024606 amino acid Drugs 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 239000011365 complex material Substances 0.000 claims 4
- 239000000758 substrate Substances 0.000 claims 4
- 241001465754 Metazoa Species 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 235000018102 proteins Nutrition 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 102000005962 receptors Human genes 0.000 claims 3
- 108020003175 receptors Proteins 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 101710112752 Cytotoxin Proteins 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 2
- 229930126263 Maytansine Natural products 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 229930012538 Paclitaxel Natural products 0.000 claims 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 2
- 239000004473 Threonine Substances 0.000 claims 2
- 229940122803 Vinca alkaloid Drugs 0.000 claims 2
- 238000001261 affinity purification Methods 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 235000009582 asparagine Nutrition 0.000 claims 2
- 229960001230 asparagine Drugs 0.000 claims 2
- 108010044540 auristatin Proteins 0.000 claims 2
- 238000012412 chemical coupling Methods 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims 2
- 239000002619 cytotoxin Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229930013356 epothilone Natural products 0.000 claims 2
- 150000003883 epothilone derivatives Chemical class 0.000 claims 2
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical group CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 claims 2
- 150000007523 nucleic acids Chemical group 0.000 claims 2
- 229960001592 paclitaxel Drugs 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 230000002285 radioactive effect Effects 0.000 claims 2
- 239000000700 radioactive tracer Substances 0.000 claims 2
- 238000007142 ring opening reaction Methods 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 2
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 101150029707 ERBB2 gene Proteins 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 108090000279 Peptidyltransferases Proteins 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 239000007983 Tris buffer Substances 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims 1
- 0 CC[C@](C)[C@@]([C@@](CC(N(CCC1)[C@@]1[C@@]([C@@](C)C(N[C@](C)[C@](c1ccccc1)O)=O)OC)=O)OC)N(C)C([C@](C(C)C)NC([C@](C(C)C)N(C)C(OCc(cc1)ccc1NC([C@](CCCNC(N)=O)NC([C@](C(C)C)NC(CCCCCNC(C(CC(O)=O)SCC(C(NCC(*)=O)=O)NC(C)(C)C(CNC(C)C)=O)=O)=O)=O)=O)=O)=O)=O Chemical compound CC[C@](C)[C@@]([C@@](CC(N(CCC1)[C@@]1[C@@]([C@@](C)C(N[C@](C)[C@](c1ccccc1)O)=O)OC)=O)OC)N(C)C([C@](C(C)C)NC([C@](C(C)C)N(C)C(OCc(cc1)ccc1NC([C@](CCCNC(N)=O)NC([C@](C(C)C)NC(CCCCCNC(C(CC(O)=O)SCC(C(NCC(*)=O)=O)NC(C)(C)C(CNC(C)C)=O)=O)=O)=O)=O)=O)=O)=O 0.000 description 5
- FZQXXDOBAFDTEP-WXJVFSNFSA-N CN(C([C@@H](C12)C1SI)=O)C2=O Chemical compound CN(C([C@@H](C12)C1SI)=O)C2=O FZQXXDOBAFDTEP-WXJVFSNFSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410174890.8 | 2014-04-29 | ||
| CN201410174890 | 2014-04-29 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016563404A Division JP6666264B2 (ja) | 2014-04-29 | 2015-04-29 | 新規安定型抗体薬物複合体の作製およびその応用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020055828A JP2020055828A (ja) | 2020-04-09 |
| JP2020055828A5 true JP2020055828A5 (enExample) | 2020-08-06 |
| JP7100617B2 JP7100617B2 (ja) | 2022-07-13 |
Family
ID=54358190
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016563404A Active JP6666264B2 (ja) | 2014-04-29 | 2015-04-29 | 新規安定型抗体薬物複合体の作製およびその応用 |
| JP2019215918A Active JP7100617B2 (ja) | 2014-04-29 | 2019-11-29 | 新規安定型抗体薬物複合体の作製およびその応用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016563404A Active JP6666264B2 (ja) | 2014-04-29 | 2015-04-29 | 新規安定型抗体薬物複合体の作製およびその応用 |
Country Status (8)
| Country | Link |
|---|---|
| US (5) | US11040084B2 (enExample) |
| EP (2) | EP3517114A1 (enExample) |
| JP (2) | JP6666264B2 (enExample) |
| KR (1) | KR102511249B1 (enExample) |
| CN (2) | CN106856656B (enExample) |
| AU (2) | AU2015252518B2 (enExample) |
| ES (1) | ES2736505T3 (enExample) |
| WO (1) | WO2015165413A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3517114A1 (en) | 2014-04-29 | 2019-07-31 | Genequantum Healthcare (Suzhou) Co., Ltd. | New stable antibody-drug conjugate, preparation method and use thereof |
| BR112019000071A2 (pt) | 2016-07-07 | 2019-07-02 | Bolt Biotherapeutics Inc | conjugados adjuvantes de anticorpo |
| EP3937984A1 (en) | 2019-03-15 | 2022-01-19 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
| CN114901694A (zh) * | 2019-12-31 | 2022-08-12 | 启德医药科技（苏州）有限公司 | 抗trop2抗体、抗体-药物缀合物及其应用 |
| WO2021136475A1 (en) * | 2019-12-31 | 2021-07-08 | Genequantum Healthcare (Suzhou) Co., Ltd. | A drug conjugate and applications thereof |
| US20230399616A1 (en) * | 2020-10-30 | 2023-12-14 | Westlake Therapeutics (Hangzhou) Co. Limited | Modified Red Blood Cells and Uses Thereof for Delivering Agents |
| AU2020482800B2 (en) * | 2020-12-23 | 2025-08-21 | Genequantum Healthcare (Suzhou) Co., Ltd. | Novel isomeric compounds comprising a ring-opened thiosuccinimide group, an oligopeptide fragment and a chiral moiety |
| KR20230147105A (ko) | 2021-01-28 | 2023-10-20 | 진콴텀 헬스케어 (쑤저우) 씨오., 엘티디. | 리가제 융합 단백질 및 그 응용 |
| WO2022188743A1 (en) * | 2021-03-08 | 2022-09-15 | Genequantum Healthcare (Suzhou) Co., Ltd. | Anti-her2 antibody-immune agonist conjugate and applications thereof |
| JP7844499B2 (ja) * | 2021-03-08 | 2026-04-13 | ジーンクアンタム ヘルスケア （スーチョウ） シーオー．， エルティーディー． | 抗体－免疫アゴニストコンジュゲート及びその使用 |
| CN115197297B (zh) * | 2021-04-14 | 2023-08-01 | 启德医药科技（苏州）有限公司 | 连接子、缀合物及其应用 |
| US20240238440A1 (en) * | 2021-04-29 | 2024-07-18 | Hyslink Therapeutics | Preparation method for and application of antibody conjugated drug |
| US11814394B2 (en) * | 2021-11-16 | 2023-11-14 | Genequantum Healthcare (Suzhou) Co., Ltd. | Exatecan derivatives, linker-payloads, and conjugates and thereof |
| US20250043005A1 (en) * | 2021-12-09 | 2025-02-06 | Genequantum Healthcare (Suzhou) Co., Ltd. | Antibody-cytokine fusion proteins and applications thereof |
| US20250213484A1 (en) * | 2022-03-29 | 2025-07-03 | Genequantum Healthcare (Suzhou) Co., Ltd. | A freeze-drying process for an adc |
| JP7893907B2 (ja) | 2022-06-02 | 2026-07-22 | ジーンクアンタム ヘルスケア （スーチョウ） シーオー．， エルティーディー． | オリゴ糖リンカー、オリゴ糖リンカーを含むリンカー－ペイロード、および糖鎖がリモデリングされた抗体薬物複合体、その製造方法と使用 |
| KR20250068592A (ko) * | 2022-06-28 | 2025-05-16 | 진콴텀 헬스케어 (쑤저우) 씨오., 엘티디. | 항-fgfr3 항체 접합체 및 이의 의학적 용도 |
| KR20250031198A (ko) | 2022-07-01 | 2025-03-06 | 진콴텀 헬스케어 (쑤저우) 씨오., 엘티디. | 고정화된 엔도글리코시다아제 융합 단백질 및 이의 적용 |
| AU2023305694A1 (en) * | 2022-07-15 | 2025-02-20 | Genequantum Healthcare (Suzhou) Co., Ltd. | Linkers, conjugates and applications thereof |
| WO2024012566A2 (en) | 2022-07-15 | 2024-01-18 | Genequantum Healthcare (Suzhou) Co., Ltd. | Antibody, linkers, payload, conjugates and applications thereof |
| AU2023328010A1 (en) | 2022-08-25 | 2025-03-20 | Genequantum Healthcare (Suzhou) Co., Ltd. | Pharmaceutical composition of antibody drug conjugate |
| WO2024078612A1 (en) * | 2022-10-14 | 2024-04-18 | Genequantum Healthcare (Suzhou) Co., Ltd. | Linker-payload compound, conjugates and applications thereof |
| WO2024193570A1 (en) * | 2023-03-21 | 2024-09-26 | Genequantum Healthcare (Suzhou) Co., Ltd. | Combination of antibody-drug conjugate and cancer therapy, and use thereof |
| CN120981487A (zh) * | 2023-03-30 | 2025-11-18 | 启德医药科技（苏州）有限公司 | 位点特异性正交生物偶联模式及其应用 |
| JP2026515759A (ja) | 2023-04-13 | 2026-05-19 | ジーンクオンタム ヘルスケア （スーチョウ） カンパニー リミテッド | 抗体－薬物コンジュゲートと抗ｐｄ－１抗体との組み合わせ、及びその使用 |
| WO2025113659A1 (zh) | 2023-12-01 | 2025-06-05 | 启德医药科技（苏州）有限公司 | 三糖连接子，包含三糖连接子的连接子-负载物和糖链重塑的抗体偶联药物，其制备方法和用途 |
| AR134906A1 (es) | 2024-01-12 | 2026-05-06 | Genequantum Healthcare Suzhou Co Ltd | Composición farmacéutica |
| WO2025255054A1 (en) * | 2024-06-03 | 2025-12-11 | Darbix Llc | Methods and compositions for oligonucleotide bioconjugation |
| WO2026133302A1 (en) | 2024-12-22 | 2026-06-25 | Biohaven Therapeutics Ltd. | Mouth wash for use with anti-trop2 antibody-drug conjugates |
| WO2026150353A2 (en) | 2025-01-11 | 2026-07-16 | Biohaven Therapeutics Ltd. | Antibody-drug conjugates for delivering cytotoxic agents |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6028056A (en) * | 1998-02-06 | 2000-02-22 | Diatide, Inc. | Pharmaceutical compositions for imaging and treating thrombi |
| ES2605443T3 (es) | 2003-11-06 | 2017-03-14 | Seattle Genetics, Inc. | Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia |
| US7241020B2 (en) * | 2003-11-20 | 2007-07-10 | Mirror Lite | High definition vehicular mirror |
| NZ551180A (en) | 2004-06-01 | 2009-10-30 | Genentech Inc | Antibody drug conjugates and methods |
| UA108598C2 (xx) * | 2008-04-30 | 2015-05-25 | Високоефективні кон'югати та гідрофільні зшиваючі агенти (лінкери) | |
| US8940501B2 (en) | 2009-01-30 | 2015-01-27 | Whitehead Institute For Biomedical Research | Methods for ligation and uses thereof |
| US9504756B2 (en) | 2012-05-15 | 2016-11-29 | Seattle Genetics, Inc. | Self-stabilizing linker conjugates |
| EP2904089A4 (en) * | 2012-10-04 | 2016-05-25 | Immunogen Inc | USE OF A PVDF MEMBRANE FOR PURIFYING CELL BINDING AGENT-CYTOTOXIC AGENT CONJUGATES |
| EP2777714A1 (en) | 2013-03-15 | 2014-09-17 | NBE-Therapeutics LLC | Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme |
| EP2988786A4 (en) * | 2013-04-22 | 2016-12-21 | Avelas Biosciences Inc | COMPOSITIONS FOR SELECTIVE DRUG ADMINISTRATION AND METHOD OF USE |
| GB2529356B (en) * | 2013-04-28 | 2020-12-23 | Genequantum Healthcare Co Ltd | Novel linkers, coupling intermediates, conjugates, preparation method and application thereof |
| EP3517114A1 (en) | 2014-04-29 | 2019-07-31 | Genequantum Healthcare (Suzhou) Co., Ltd. | New stable antibody-drug conjugate, preparation method and use thereof |
| CN107828351B (zh) | 2016-09-15 | 2021-07-27 | E·I·内穆尔杜邦公司 | 用于粘合的导电糊料 |
| JP2021531826A (ja) | 2018-07-09 | 2021-11-25 | ジーンクアンタム ヘルスケア (スーチョウ) シーオー., エルティーディー.Genequantum Healthcare (Suzhou)Co., Ltd. | 栄養膜細胞表面抗原２（ｔｒｏｐ２）に対する特異的な抗体 |
| CN114901694A (zh) | 2019-12-31 | 2022-08-12 | 启德医药科技（苏州）有限公司 | 抗trop2抗体、抗体-药物缀合物及其应用 |
| KR20230147105A (ko) | 2021-01-28 | 2023-10-20 | 진콴텀 헬스케어 (쑤저우) 씨오., 엘티디. | 리가제 융합 단백질 및 그 응용 |
| ES3031876T3 (en) | 2021-02-09 | 2025-07-11 | Genequantum Healthcare Suzhou Co Ltd | Conjugation device and method for producing conjugates |
| JP7844499B2 (ja) | 2021-03-08 | 2026-04-13 | ジーンクアンタム ヘルスケア （スーチョウ） シーオー．， エルティーディー． | 抗体－免疫アゴニストコンジュゲート及びその使用 |
| CN115197297B (zh) | 2021-04-14 | 2023-08-01 | 启德医药科技（苏州）有限公司 | 连接子、缀合物及其应用 |
-
2015
- 2015-04-29 EP EP19157398.9A patent/EP3517114A1/en not_active Withdrawn
- 2015-04-29 JP JP2016563404A patent/JP6666264B2/ja active Active
- 2015-04-29 WO PCT/CN2015/077887 patent/WO2015165413A1/zh not_active Ceased
- 2015-04-29 KR KR1020167033391A patent/KR102511249B1/ko active Active
- 2015-04-29 AU AU2015252518A patent/AU2015252518B2/en active Active
- 2015-04-29 CN CN201580023609.3A patent/CN106856656B/zh active Active
- 2015-04-29 US US15/307,738 patent/US11040084B2/en active Active
- 2015-04-29 EP EP15786402.6A patent/EP3138568B1/en active Active
- 2015-04-29 ES ES15786402T patent/ES2736505T3/es active Active
- 2015-10-09 CN CN202110225700.0A patent/CN112999362B/zh active Active
-
2019
- 2019-11-29 JP JP2019215918A patent/JP7100617B2/ja active Active
-
2020
- 2020-02-11 AU AU2020200975A patent/AU2020200975B2/en active Active
-
2021
- 2021-02-19 US US17/180,645 patent/US11911435B2/en active Active
- 2021-02-19 US US17/180,412 patent/US11911434B2/en active Active
-
2024
- 2024-01-10 US US18/408,826 patent/US20240156894A1/en active Pending
- 2024-01-11 US US18/410,200 patent/US20240165192A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017514812A5 (enExample) | ||
| JP7467526B2 (ja) | 操作された抗体化合物およびこれらの抱合体 | |
| US7364859B2 (en) | Methods of using bioelastomers | |
| CN104262460B (zh) | 一种靶向人乳腺癌细胞的多肽及其应用 | |
| KR20250047840A (ko) | 항체-약물 콘주게이트의 신규 제조 방법 | |
| JP2021521822A5 (enExample) | ||
| JP2018138588A (ja) | 新規リンカー、その製造方法およびその応用 | |
| Zdobnova et al. | Self-assembling complexes of quantum dots and scFv antibodies for cancer cell targeting and imaging | |
| JP2014506135A5 (enExample) | ||
| CN101750486A (zh) | 用一类基于与组氨酸结合生成荧光基团的铱配合物标记抗体 | |
| CN104130315B (zh) | 一种特异靶向her2蛋白的多肽 | |
| CN105198964A (zh) | 一种肿瘤靶向多肽、其制备方法及应用 | |
| CN105085631B (zh) | 一种特异靶向her2蛋白的多肽及其应用 | |
| CN111971060A (zh) | 募集抗体并靶向肿瘤细胞的双功能分子 | |
| CN105330725B (zh) | 一种pH响应且靶向人肿瘤血管标记物VEGFR2的多肽及其应用 | |
| Calce et al. | HER2-mediated anticancer drug delivery: strategies to prepare targeting ligands highly specific for the receptor | |
| KR102890061B1 (ko) | 인광 기반 바이오 융합 소재 및 이의 용도 | |
| JP2006514919A (ja) | 新規な誘導システムの合成及び特徴付け、並びに標的細胞への治療対象分子のベクター化 | |
| JP4860352B2 (ja) | 診断薬及びそれを用いた測定方法 | |
| CN119192296A (zh) | 一种多肽类化合物及药物组合物和应用 | |
| CN102168104A (zh) | 用于标记生物分子的编码分子及其制备方法 | |
| WO2023212906A1 (en) | Antibodis comprising engineered hinge and uses thereof | |
| JP5539920B2 (ja) | 診断薬及びそれを用いた測定方法 | |
| KR102376443B1 (ko) | 나노구조체, 나노구조체를 포함하는 바이오센서, 및 스크리닝 방법 | |
| CN116284224A (zh) | 一种结合Claudin 18.2的环肽及其应用 |